Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Discover Why Claritox Pro is 2025’s Leading Natural Supplement for Dizziness, Balance, and Mental Clarity Without Harsh ...

Evening events offer high-impact, case-based learning with top experts—available in person or virtuallyCHICAGO, April 25, ...

A promising diversified healthcare offering. Our research team assigns Bronze ratings to strategies they’re confident will outperform a relevant index, or most peers, over a market cycle on a ...

RPG Life Sciences Ltd., incorporated in the year 2007, is a Small Cap company (having a market cap of Rs 3,711.85 Crore) operating in Pharmaceuticals sector. RPG Life Sciences Ltd. key ...

Krishna Institute of Medical Sciences Ltd., incorporated in the year 1973, is a Small Cap company (having a market cap of Rs 26,693.27 Crore) operating in Hospitals & Allied Services sector. Krishna ...